iPS Cells & Regenerative Medicine– category –
-
Regenxbio’s Hunter Syndrome Gene Therapy Refiling Halted by Second FDA Clinical Hold
Fierce Biotech USA Overview Regenxbio's plan to refile its gene therapy for Hunter syndrome (MPS II) has been derailed by a clinical hold imposed by the FDA, leading the company to postpone its regulatory submission indefinitely. This ma... -
Broad Institute Achieves Long-Term Brain Organoid Longevity and Streamlines Prime Editing with AI
Broad Institute USA Overview The Broad Institute announced a significant milestone on August 20, 2026, where an AI model streamlined the prime editing process and enabled the long-term longevity of brain organoids. The institute actively... -
Cellistic Expands iPSC Therapy Manufacturing with New GMP Platforms for Immuno-Oncology and Regenerative Medicine
Cellistic Press Release (via PharmaTimes) Belgium Overview Cellistic has introduced three new GMP manufacturing platforms—Echo-T, Echo-Cardio, and Echo-Endothelial—significantly expanding its capabilities for iPSC-derived cell therapies.... -
Global Summits Confront Cell & Gene Therapy Scale-Up: Automation, Cost Efficiency, and Mass Production Strategies
Informa Connect International Overview Upcoming international conferences, including Advanced Therapies Europe and the CAR-TCR Summit in September 2026, are set to address the urgent need for scalable and cost-effective manufacturing in ... -
Exosome-Based Therapeutics Development Summit Convenes in Boston to Address Manufacturing, Regulatory, and Clinical Challenges
Hanson Wade Conferences USA Overview The 8th Exosome-Based Therapeutics Development Summit will be held in Boston from September 22-24, 2026, focusing on overcoming challenges in scalable manufacturing, robust analytical characterization... -
AI-Driven ‘GRACE’ System Poised to Revolutionize 3D Bioprinting, Address Organ Shortages; Market Expected to Hit $6.7B by 2033
TELUGU TIMES International Overview A new AI-driven system, 'GRACE,' set for unveiling in September 2025, promises to revolutionize 3D bioprinting by designing optimal vascular networks, significantly reducing cell death in bioprinted ti... -
AI-Guided 3D Bioreactors Revolutionize iPSC Manufacturing: Scaling Up and Cutting Costs for Accelerated Commercialization
Wiley Analytical Science USA Overview AI-guided 3D bioreactor technology is revolutionizing iPSC manufacturing, enabling reliable, efficient, and scalable production of pluripotent stem cells (PSCs). This innovative platform facilitates ... -
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
Precision BioSciences Initiates Phase 1/2 FUNCTION-DMD Clinical Trial for PBGENE-DMD Gene Therapy: Applicable to 60% of DMD Patients, Initial Safety Data Expected by Year-End
Precision BioSciences, Inc. (Press Release) USA Overview Precision BioSciences announced the initiation of patient dosing in its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, an in vivo gene editing therapy for Duchenne muscular ... -
Mayo Clinic Leads ARPA-H Initiative to Advance Gene-Editing Therapies for Rare Immune Diseases, Integrating CRISPR and Novel Delivery for Over 500 Inborn Errors of Immunity
Mayo Clinic News Network USA Overview Mayo Clinic is participating in a 5-year collaborative research initiative, funded by an ARPA-H grant, to accelerate the development of gene-editing therapies for rare immune diseases. This initiativ...
